IPM Welcomes FDA Approval of Truvada

The International Partnership for Microbicides welcomes the US Food and Drug Administration (FDA) decision July 16 to approve Truvada as pre-exposure prophylaxis (PrEP) to prevent HIV infection in sexually active HIV-negative adult men and women. This decision expands the range of HIV prevention options available to those who need them most and we applaud those who helped  make this decision possible.

It is crucial to maintain focus on the power of ARV-based prevention and explore additional effective tools that suit individuals' preferences and empower them to protect their health. IPM is committed to developing ARV-based prevention technologies for women and recently launched a Phase III trial of a vaginal ARV-containing microbicide ring in South Africa. 

At next week’s International AIDS Society’s biennial conference, we look forward to discussing PrEP, microbicides and other emerging ARV-based prevention strategies that are revolutionizing the world's response to HIV.   

For more information on the FDA’s decision, please see the FDA press statement. For more information on Truvada, please see the press statement released by Gilead, which developed Truvada.